[go: up one dir, main page]

WO2002043756A3 - Método de obtención de agregados antigénicos y su uso en formulaciones - Google Patents

Método de obtención de agregados antigénicos y su uso en formulaciones Download PDF

Info

Publication number
WO2002043756A3
WO2002043756A3 PCT/CU2001/000009 CU0100009W WO0243756A3 WO 2002043756 A3 WO2002043756 A3 WO 2002043756A3 CU 0100009 W CU0100009 W CU 0100009W WO 0243756 A3 WO0243756 A3 WO 0243756A3
Authority
WO
WIPO (PCT)
Prior art keywords
structures
resulting
aggregate
formulations
antigenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CU2001/000009
Other languages
English (en)
French (fr)
Other versions
WO2002043756A2 (es
Inventor
Rubido Julio Cesar Aguilar
Arias Eduardo Penton
Dina Tleugabulova
Mensies Minerva Sewer
Gonzalez Verena Lucila Muzio
Nieto Gerardo Enrique Guillen
Bernard Iloki Assanga Simon
Ricondo Luis Javier Cruz
Cama Viviana Falcon
Hernandez Yanet Tambara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002545726A priority Critical patent/JP4974441B2/ja
Priority to BRPI0115859-7 priority patent/BRPI0115859B8/pt
Priority to US10/433,492 priority patent/US20040202676A1/en
Priority to CA2429543A priority patent/CA2429543C/en
Priority to KR1020037007094A priority patent/KR100873675B1/ko
Priority to AU2002221518A priority patent/AU2002221518B2/en
Priority to DE60141978T priority patent/DE60141978D1/de
Priority to AU2151802A priority patent/AU2151802A/xx
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority to EP01998363A priority patent/EP1346727B1/en
Priority to AT01998363T priority patent/ATE465752T1/de
Publication of WO2002043756A2 publication Critical patent/WO2002043756A2/es
Publication of WO2002043756A3 publication Critical patent/WO2002043756A3/es
Anticipated expiration legal-status Critical
Priority to US11/870,088 priority patent/US20090104223A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se relaciona con un método de obtención de estructuras antigénicas agregadas, capaces de potenciar la respuesta inmune a antígenos agregados administrados por vía sistémica y/o mucosal, así como con las estructuras químicas, formulaciones de dichas estructuras y su uso. A partir del uso de agentes o compuestos agregantes, delipidantes u oxidantes, se permite la liberación de lípidos de las partículas y la agregación de las mismas. El estado de agregación se puede provocar en el interior de la levadura variando las condiciones de incubación. Las estructuras resultantes pueden utilizarse adyuvadas y/o con varios antígenos, produciéndose sinergismo entre los componentes con respecto a la respuesta inmunogénica , pudiendo contener estabilizadores y preservos. Estas nuevas estructuras antigénicas son aplicables en la industria como formulaciones vacunales, preventivas o terapéuticas, para uso humano, veterinario y /o diagnóstico.
PCT/CU2001/000009 2000-12-01 2001-11-29 Método de obtención de agregados antigénicos y su uso en formulaciones Ceased WO2002043756A2 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DE60141978T DE60141978D1 (de) 2000-12-01 2001-11-29 Verfahren zur gewinnung delipidierter antigener aggregate von hepatitis b und deren verwendung
US10/433,492 US20040202676A1 (en) 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations
CA2429543A CA2429543C (en) 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations
KR1020037007094A KR100873675B1 (ko) 2000-12-01 2001-11-29 항원응집체의 수득방법 및 제제에서의 이의 용도
AU2002221518A AU2002221518B2 (en) 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations
AU2151802A AU2151802A (en) 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations
EP01998363A EP1346727B1 (en) 2000-12-01 2001-11-29 Method for obtaining delipidated hepatitis b antigenic aggregates and their use thereof
JP2002545726A JP4974441B2 (ja) 2000-12-01 2001-11-29 抗原性凝集物を得る方法と製剤におけるその使用
BRPI0115859-7 BRPI0115859B8 (pt) 2000-12-01 2001-11-29 método de obtenção de estruturas antigênicas agregadas de alta imunogenicidade, estrutura antigênica agregada, formulação de vacina e usos de uma estrutura antigênica e de formulações de vacina
AT01998363T ATE465752T1 (de) 2000-12-01 2001-11-29 Verfahren zur gewinnung delipidierter antigener aggregate von hepatitis b und deren verwendung
US11/870,088 US20090104223A1 (en) 2000-12-01 2007-10-10 Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2000-0279 2000-12-01
CU20000279A CU23002A1 (es) 2000-12-01 2000-12-01 Método de obtención de agregados antigénicos y su uso en formulaciones

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/870,088 Division US20090104223A1 (en) 2000-12-01 2007-10-10 Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations

Publications (2)

Publication Number Publication Date
WO2002043756A2 WO2002043756A2 (es) 2002-06-06
WO2002043756A3 true WO2002043756A3 (es) 2003-01-09

Family

ID=5459569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2001/000009 Ceased WO2002043756A2 (es) 2000-12-01 2001-11-29 Método de obtención de agregados antigénicos y su uso en formulaciones

Country Status (17)

Country Link
US (2) US20040202676A1 (es)
EP (1) EP1346727B1 (es)
JP (1) JP4974441B2 (es)
KR (1) KR100873675B1 (es)
CN (1) CN1253206C (es)
AR (1) AR031437A1 (es)
AT (1) ATE465752T1 (es)
AU (2) AU2151802A (es)
BR (1) BRPI0115859B8 (es)
CA (1) CA2429543C (es)
CU (1) CU23002A1 (es)
DE (1) DE60141978D1 (es)
ES (1) ES2342150T3 (es)
PT (1) PT1346727E (es)
RU (1) RU2266754C2 (es)
WO (1) WO2002043756A2 (es)
ZA (1) ZA200303948B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
US9603921B2 (en) 2004-10-27 2017-03-28 Janssen Vaccines Ag Virosome particles comprising antigens from influenza virus and hepatitis b virus
EP1652914A1 (en) * 2004-10-27 2006-05-03 Berna Biotech AG Virosome particles comprising antigens from influenza virus and Hepatitis B virus
EP2623116A1 (en) * 2005-07-27 2013-08-07 Eli Lilly and Company A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
AR107262A1 (es) 2016-01-27 2018-04-11 Lilly Co Eli Inactivación de patógenos por delipidación
US11491218B2 (en) 2016-03-31 2022-11-08 Centro De Ingeniería Genética Y Biotecnología Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis B virus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174759A1 (en) * 1984-08-22 1986-03-19 Connaught Laboratories Limited Multispecific immunogenic proteins
EP0231039A1 (en) * 1986-01-14 1987-08-05 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728804A (en) * 1995-06-02 1998-03-17 Research Corporation Technologies, Inc. Use of cyclodextrins for protein renaturation
DE60117978T2 (de) * 2000-06-22 2006-11-02 UCB Pharma Ltd., Slough Modifizierung des hepatitis b kernantigens
US8092734B2 (en) * 2004-05-13 2012-01-10 Aptina Imaging Corporation Covers for microelectronic imagers and methods for wafer-level packaging of microelectronics imagers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174759A1 (en) * 1984-08-22 1986-03-19 Connaught Laboratories Limited Multispecific immunogenic proteins
EP0231039A1 (en) * 1986-01-14 1987-08-05 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BABAEVA E E ET AL: "ANTIGENIC DETERMINANTS OF NORMAL SERUM PROTEINS ASSOCIATED WITH HEPATITIS B VIRUS HEPATITIS B SURFACE ANTIGEN", VOPROSY VIRUSOLOGII, no. 4, 1981, pages 442 - 446, XP002209718, ISSN: 0507-4088 *

Also Published As

Publication number Publication date
AU2002221518B2 (en) 2006-06-01
EP1346727B1 (en) 2010-04-28
CA2429543C (en) 2012-07-10
WO2002043756A2 (es) 2002-06-06
JP4974441B2 (ja) 2012-07-11
US20090104223A1 (en) 2009-04-23
CN1477972A (zh) 2004-02-25
CU23002A1 (es) 2004-11-18
ZA200303948B (en) 2004-03-30
JP2004529861A (ja) 2004-09-30
CN1253206C (zh) 2006-04-26
BR0115859A (pt) 2003-12-30
AU2151802A (en) 2002-06-11
ES2342150T3 (es) 2010-07-02
RU2266754C2 (ru) 2005-12-27
BRPI0115859B1 (pt) 2020-10-13
KR20030068161A (ko) 2003-08-19
CA2429543A1 (en) 2003-05-20
DE60141978D1 (de) 2010-06-10
ATE465752T1 (de) 2010-05-15
US20040202676A1 (en) 2004-10-14
BRPI0115859B8 (pt) 2021-05-25
AR031437A1 (es) 2003-09-24
PT1346727E (pt) 2010-05-21
KR100873675B1 (ko) 2008-12-11
EP1346727A2 (en) 2003-09-24

Similar Documents

Publication Publication Date Title
WO2000050006A3 (en) Microemulsions with adsorbed macromoelecules and microparticles
Kreuter et al. The use of new polymethylmethacrylate adjuvants for split influenza vaccines
CA2529363A1 (en) Quil a fraction with low toxicity and use thereof
WO2001060402A3 (en) Proteosome influenza vaccine
US9585955B2 (en) Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
EP1490106B1 (de) Verwendung eines lipopeptids oder lipoproteins als adjuvans bei therapeutischer oder prophylaktischer vakzinierung
WO2003051394A3 (en) Calcium phosphate particles as mucosal adjuvants
Eng et al. The potential of polyphosphazenes for delivery of vaccine antigens and immunotherapeutic agents
CA2563371A1 (en) Methods of manufacture and use of calcium phosphate particles containing allergens
WO2002043756A3 (es) Método de obtención de agregados antigénicos y su uso en formulaciones
AU769375B2 (en) Vaccine formulation
AU769390B2 (en) Vaccine composition
Glück et al. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems
Kreuter et al. Protection induced by inactivated influenza virus vaccines with polymethylmethacrylate adjuvants
WO2000062802A3 (en) Vaccine comprising rsv antigen and cpg oligonucleotide
EP2174665A3 (en) Compositions and methods for activating innate and allergic immunity
WO2002036160A3 (es) Método de obtención de estructuras antigénicas que potencian la reactividad cruzada específica
NO902352D0 (no) Fremgangsmaate for fremstilling av en vaksine mot dental karies, samt vaksineblandinger for anvendelse som nesedraaper
Ekström et al. Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions
Cameron Comparative efficacy of six Brucella vaccines in guinea-pigs
Garçon Delivery systems: the long road to human vaccines
WO2000057919A3 (en) Lipid-based artificial particles inducing cell-mediated immunity
SI0701612T1 (en) IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 770/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2429543

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003/03948

Country of ref document: ZA

Ref document number: 200303948

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002221518

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020037007094

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018198236

Country of ref document: CN

Ref document number: 2002545726

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001998363

Country of ref document: EP

ENP Entry into the national phase

Ref country code: RU

Ref document number: RU A

WWP Wipo information: published in national office

Ref document number: 1020037007094

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001998363

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10433492

Country of ref document: US